Oesophageal cancer

Elizabeth Smyth(National Health Service), David Cunningham(Royal Marsden NHS Foundation Trust), Rebecca C. Fitzgerald(Cancer Research UK), Jesper Lagergren(Karolinska University Hospital), Pernilla Lagergren(Imperial College London), Florian Lordick(Leipzig University), Manish A. Shah(NewYork–Presbyterian Hospital)
Nature Reviews Disease Primers
July 27, 2017
10.1038/nrdp.2017.48
Cited by 1,074

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k